Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Portfolio Pulse from
Levi & Korsinsky has filed a class action securities lawsuit against Intellia Therapeutics, alleging the company misled investors about its NTLA-3001 research program. The lawsuit claims Intellia failed to disclose the declining demand for viral-based editing and subsequently halted the program, leading to a 15% stock price drop in January 2025.
April 11, 2025 | 10:00 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intellia Therapeutics is facing a class action lawsuit alleging securities fraud related to its NTLA-3001 research program, which was unexpectedly halted in January 2025.
The lawsuit alleges material misrepresentations about the NTLA-3001 program, which could negatively impact investor confidence and potentially result in financial penalties.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100